Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
The National Institute for Health and Care Excellence has preliminary support for two new options for the treatment of diabetic macular oedema.
Diabetic macular oedema is caused when blood vessels abnormally form under the retina and then begin to break down causing plasma to leak into the eye.
The leakage is due to a reduction in the amount of connective tissues around the blood vessels and an increased amount of vascular endothelial growth factor. The resulting oedema can lead to severe visual impairment.
In draft guidance, published today, aflibercept (Eylea) is recommended by NICE where the eye has a central retinal thickness of 400 micrometres or more at the start of treatment.
http://www.nursingtimes.net/nursing...ts-for-diabetic-eye-condition/5082555.article
(free registration required)
Diabetic macular oedema is caused when blood vessels abnormally form under the retina and then begin to break down causing plasma to leak into the eye.
The leakage is due to a reduction in the amount of connective tissues around the blood vessels and an increased amount of vascular endothelial growth factor. The resulting oedema can lead to severe visual impairment.
In draft guidance, published today, aflibercept (Eylea) is recommended by NICE where the eye has a central retinal thickness of 400 micrometres or more at the start of treatment.
http://www.nursingtimes.net/nursing...ts-for-diabetic-eye-condition/5082555.article
(free registration required)